KRAS and neoplasm: KRAS‐EphA‐2‐CAR‐DC can suppress the growth of tumours expressing the correlated KRAS mutant in animal models. In addition, the combination of the immune checkpoint inhibitors could further reverse immunosuppressive TME and globally activate T‐cell responses.